Verrica Pharmaceuticals Inc. announced that it received the minutes from the Company's recent Type C meeting with the U.S. Food and Drug Administration (FDA), which was held on November 6, 2023, to discuss the Phase 3 clinical development plan for YCANTH for the treatment of common warts. More specifically, the Company believes that the Type C meeting satisfied its objective to gain the FDA's advice and agreement on the overall design of a pivotal Phase 3 study of YCANTH that would support an efficacy supplement for the proposed indication of common warts. YCANTH is currently only approved to treat molluscum contagiosum in adults and children two years of age and older.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.87 USD | +3.31% | -1.58% | -6.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.15% | 291M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- VRCA Stock
- News Verrica Pharmaceuticals Inc.
- Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH?? for the Treatment of Common Warts